Stock Split History
ETFs Holding PTGX »    PTGX Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop peptide-based drugs. Co.'s clinical asset, PTG-300, is an injectable hepcidin mimetic in development for the potential treatment of iron overload and other blood disorders. Co. is developing PTG-300 for the treatment of ineffective erythropoiesis, chronic anemia and iron overload, with an initial focus on beta-thalassemia non-transfusion dependent and transfusion dependent patients. Co.'s other clinical assets, PTG-200 and PN-943, are orally delivered drugs in development for inflammatory bowel disease. According to our Protagonist Therapeutics stock split history records, Protagonist Therapeutics has had 0 splits.
Protagonist Therapeutics stock split history picture
Protagonist Therapeutics (PTGX) has 0 splits in our Protagonist Therapeutics stock split history database.

Looking at the Protagonist Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Protagonist Therapeutics shares, starting with a $10,000 purchase of PTGX, presented on a split-history-adjusted basis factoring in the complete Protagonist Therapeutics stock split history. Protagonist Therapeutics split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/12/2016
End date: 05/17/2021
Start price/share: $11.57
End price/share: $30.07
Dividends collected/share: $0.00
Total return: 159.90%
Average Annual Total Return: 22.20%
Starting investment: $10,000.00
Ending investment: $25,992.06
Years: 4.76
Date Ratio
LM Funding America, Inc. (LMFA)
Foxby Corp. (XFXBX)
InspireMD, Inc. (NSPR)
Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Protagonist Therapeutics
Protagonist Therapeutics Insider Buying

Protagonist Therapeutics Stock Split History | | Copyright © 2013 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.